Tokio Marine Asset Management Co. Ltd. Raises Holdings in Boston Scientific Co. (NYSE:BSX)

Tokio Marine Asset Management Co. Ltd. raised its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 15.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 36,820 shares of the medical equipment provider’s stock after buying an additional 4,889 shares during the period. Tokio Marine Asset Management Co. Ltd.’s holdings in Boston Scientific were worth $2,129,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. AE Wealth Management LLC grew its holdings in shares of Boston Scientific by 9.9% during the third quarter. AE Wealth Management LLC now owns 34,374 shares of the medical equipment provider’s stock valued at $1,815,000 after buying an additional 3,091 shares during the last quarter. IFP Advisors Inc grew its stake in shares of Boston Scientific by 29.1% in the 3rd quarter. IFP Advisors Inc now owns 5,026 shares of the medical equipment provider’s stock valued at $265,000 after buying an additional 1,132 shares during the period. Park Place Capital Corp purchased a new position in shares of Boston Scientific during the 3rd quarter worth approximately $56,000. Private Trust Co. NA lifted its holdings in Boston Scientific by 498.8% during the 3rd quarter. Private Trust Co. NA now owns 5,132 shares of the medical equipment provider’s stock worth $271,000 after buying an additional 4,275 shares in the last quarter. Finally, Proficio Capital Partners LLC raised its holdings in shares of Boston Scientific by 9.7% in the 3rd quarter. Proficio Capital Partners LLC now owns 4,062 shares of the medical equipment provider’s stock valued at $214,000 after purchasing an additional 358 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Up 0.6 %

NYSE BSX traded up $0.44 during trading on Thursday, reaching $73.35. The company’s stock had a trading volume of 3,708,037 shares, compared to its average volume of 6,501,143. Boston Scientific Co. has a 1-year low of $48.35 and a 1-year high of $74.39. The stock has a market capitalization of $107.61 billion, a PE ratio of 68.46, a PEG ratio of 2.42 and a beta of 0.78. The company has a current ratio of 1.32, a quick ratio of 0.82 and a debt-to-equity ratio of 0.44. The business has a 50-day moving average price of $67.53 and a 200-day moving average price of $60.28.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, January 31st. The medical equipment provider reported $0.55 EPS for the quarter, beating the consensus estimate of $0.51 by $0.04. The company had revenue of $3.73 billion for the quarter, compared to the consensus estimate of $3.59 billion. Boston Scientific had a net margin of 11.19% and a return on equity of 15.99%. During the same quarter in the previous year, the company earned $0.45 EPS. On average, research analysts forecast that Boston Scientific Co. will post 2.25 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $66.89, for a total value of $467,092.87. Following the transaction, the executive vice president now directly owns 56,508 shares of the company’s stock, valued at $3,779,820.12. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, EVP Wendy Carruthers sold 6,983 shares of the business’s stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $66.89, for a total transaction of $467,092.87. Following the sale, the executive vice president now directly owns 56,508 shares in the company, valued at approximately $3,779,820.12. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Daniel J. Brennan sold 13,662 shares of the stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $65.86, for a total value of $899,779.32. Following the transaction, the chief financial officer now owns 271,542 shares in the company, valued at $17,883,756.12. The disclosure for this sale can be found here. Insiders have sold 50,979 shares of company stock worth $3,418,529 in the last 90 days. Company insiders own 0.50% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on BSX. StockNews.com downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, March 16th. Wells Fargo & Company upped their price target on shares of Boston Scientific from $72.00 to $82.00 and gave the company an “overweight” rating in a report on Thursday. Evercore ISI increased their price objective on shares of Boston Scientific from $72.00 to $78.00 and gave the stock an “outperform” rating in a report on Thursday. JPMorgan Chase & Co. lifted their price objective on shares of Boston Scientific from $72.00 to $82.00 and gave the stock an “overweight” rating in a research note on Thursday. Finally, UBS Group lifted their target price on shares of Boston Scientific from $74.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday. Three research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Boston Scientific has an average rating of “Moderate Buy” and an average target price of $74.00.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.